Medicaid Drug Rebate Program (MDRP): Quarterly State Invoice (CMS-R-144) and State Agency Contact Form (CMS-368)

ICR 202102-0938-017

OMB: 0938-0582

Federal Form Document

Forms and Documents
IC Document Collections
ICR Details
0938-0582 202102-0938-017
Received in OIRA 202003-0938-010
HHS/CMS CMCS
Medicaid Drug Rebate Program (MDRP): Quarterly State Invoice (CMS-R-144) and State Agency Contact Form (CMS-368)
Revision of a currently approved collection   No
Regular 03/01/2021
  Requested Previously Approved
36 Months From Approved 06/30/2023
290 234
13,669 12,101
0 0

Section 1927 of the Social Security Act requires each State Medicaid agency to report quarterly prescription drug utilization information to drug manufacturers and to CMS via form CMS-R-144. As part of this information, the State Medicaid agencies are required to report the total Medicaid rebate amount they claim they are owed by each drug manufacturer for each covered prescription drug product each quarter.

PL: Pub.L. 111 - 148 2501(c) Name of Law: Patient Protection and Affordable Care Act
   Statute at Large: 18 Stat. 1927 Name of Statute: null
  
PL: Pub.L. 111 - 148 2501(c) Name of Law: Patient Protection and Affordable Care Act

Not associated with rulemaking

  85 FR 76577 11/30/2020
86 FR 10971 02/23/2021
Yes

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 290 234 0 56 0 0
Annual Time Burden (Hours) 13,669 12,101 0 1,344 224 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
In this 2020/2021 iteration we have revised our per response time estimate by 1 hours (for CMS-R-144) due to the new certification requirement that was captured in the previous iteration. We have also adjusted our labor rates based on more recent BLS data. Consequently, there is a slight increase in our total time and cost estimates. Effective July 1, 2021, we are updating to a new Medicaid Drug Programs (MDP) system which will now accept a delimited text file format, Comma Separated Values (.CSV), in addition to the current Text (.TXT) file format. We have also increased several file format data field sizes in order to accommodate the higher priced drugs that are entering the market. These changes in conjunction with numerous edits to verbiage are applicable to Forms CMS-304 and CMS-304a. This PRA package (0938-0676) is simultaneously being updated along with our two corresponding PRA packages (0938-0578 and 0938-0582), so that all the MDP file formats, field sizes, and verbiage will align across the MDRP. In this regard we added a one-time burden for each manufacturer to make any system updates to accommodate the updated field sizes and .CSV file formats for CMS-R-144. Form CMS-368 has been revised by removing the DUR State Contact information and description “Drug Utilization Review (DUR) Program” in the CMS-368 header. This information is now accounted for in CMS-R-153 (OMB control number: 0938-0659). See section 15 of the Supporting Statement for more details regarding the changes.

$735
No
    No
    No
Yes
No
No
No
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/01/2021


© 2024 OMB.report | Privacy Policy